---
figid: PMC6367250__fgene-10-00016-g001
figtitle: The roles of circRNAs in cancer phenotypes and biological characteristics
organisms:
- NA
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
pmcid: PMC6367250
filename: fgene-10-00016-g001.jpg
figlink: /pmc/articles/PMC6367250/figure/F1/
number: F1
caption: The roles of circRNAs in cancer phenotypes and biological characteristics
  (proliferation, migration, invasion, and angiogenesis). First, circRNAs may function
  as miRNA sponges in cancer cells. cSMARCA5 binds to miR-17-3p and miR-181b-5p to
  inhibit the proliferation of hepatocellular carcinoma cells, which can be blocked
  by DHX9 (). CircRNA000911 binds to miR-449a to promote migration and invasion by
  targeting Notch1 and nuclear factor-κB (NF-κB) signaling (). CircRNA-MYLK binds
  to miR-29a and activates VEGFA/VEGFR2 pathway, promoting angiogenesis in bladder
  cancer (). Second, circRNAs may be translated in cancer cells. CircGpr5 encodes
  a peptide that interacts with Gprc5a and circGpr5 to promote bladder cancer ().
  Third, circRNAs can bind to proteins or function as protein decoys in cancer cells.
  CircAGO2 can bind to HuR to drive cancer progression (). Fourth, some circRNAs such
  as circ-Foxo3 can be retro-transcribed and inserted back to the genome to function
  as competitive RNA to disrupt the function of miRNAs ().
papertitle: Deregulation of Circular RNAs in Cancer From the Perspectives of Aberrant
  Biogenesis, Transport and Removal.
reftext: Qiongqiong Wu, et al. Front Genet. 2019;10:16.
year: '2019'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.8824806
figid_alias: PMC6367250__F1
figtype: Figure
redirect_from: /figures/PMC6367250__F1
ndex: ef4ef477-de8f-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6367250__fgene-10-00016-g001.html
  '@type': Dataset
  description: The roles of circRNAs in cancer phenotypes and biological characteristics
    (proliferation, migration, invasion, and angiogenesis). First, circRNAs may function
    as miRNA sponges in cancer cells. cSMARCA5 binds to miR-17-3p and miR-181b-5p
    to inhibit the proliferation of hepatocellular carcinoma cells, which can be blocked
    by DHX9 (). CircRNA000911 binds to miR-449a to promote migration and invasion
    by targeting Notch1 and nuclear factor-κB (NF-κB) signaling (). CircRNA-MYLK binds
    to miR-29a and activates VEGFA/VEGFR2 pathway, promoting angiogenesis in bladder
    cancer (). Second, circRNAs may be translated in cancer cells. CircGpr5 encodes
    a peptide that interacts with Gprc5a and circGpr5 to promote bladder cancer ().
    Third, circRNAs can bind to proteins or function as protein decoys in cancer cells.
    CircAGO2 can bind to HuR to drive cancer progression (). Fourth, some circRNAs
    such as circ-Foxo3 can be retro-transcribed and inserted back to the genome to
    function as competitive RNA to disrupt the function of miRNAs ().
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Erk7
  - rl
  - ras
  - Ras64B
  - Ras85D
  - as
  - dap
  - Cdk4
  - BC1
  - Myc
  - p53
  - betaTub60D
  - hth
  - mir-1
  - MKP-4
  - p38b
  - .na.character
  - spg
  - Akt
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - bnl
  - Pvf1
  - Pvf2
  - Pvf3
  - Pvr
  - arm
  - Wnt5
  - Wnt4
  - wg
  - Wnt2
  - EPHB2
  - MAPK1
  - MAPK3
  - KRAS
  - HRAS
  - NRAS
  - CDKN1A
  - TCEAL1
  - NSG1
  - H3P16
  - CDKL1
  - CDKL2
  - CDKL3
  - CDKL4
  - CDKL5
  - CDK3
  - CDK4
  - CDK5
  - CDK6
  - CDK7
  - CDK8
  - CDK9
  - CDK10
  - CDK11A
  - CDK11B
  - CDK12
  - CDK13
  - CDK14
  - CDK15
  - CDK16
  - CDK17
  - CDK18
  - CDK19
  - CDK20
  - CDK1
  - CDK2
  - MYC
  - TP53
  - TP63
  - TP73
  - CD59
  - FSD1
  - FSD1L
  - MIR17
  - TIMP3
  - MAPK11
  - MAPK12
  - MAPK13
  - MAPK14
  - MAPK8
  - MAPK9
  - MAPK10
  - NOTCH1
  - NOTCH2
  - NOTCH3
  - NOTCH4
  - MIR449A
  - AKT1
  - AKT2
  - AKT3
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - FGF1
  - FGF2
  - FGF3
  - FGF4
  - FGF5
  - FGF6
  - FGF7
  - FGF8
  - FGF9
  - FGF10
  - FGF11
  - FGF12
  - FGF13
  - FGF14
  - FGF16
  - FGF17
  - FGF18
  - FGF19
  - FGF20
  - FGF21
  - FGF22
  - FGF23
  - VEGFA
  - VEGFB
  - VEGFC
  - VEGFD
  - PGF
  - KDR
  - MIR29A
  - XCR1
  - ELAVL1
  - FOXO3
  - CTNNB1
  - WNT1
  - WNT2
  - WNT2B
  - WNT3
  - WNT3A
  - WNT4
  - WNT6
  - WNT7A
  - WNT7B
  - WNT8A
  - WNT8B
  - WNT9A
  - WNT9B
  - WNT10A
  - WNT10B
  - WNT11
  - WNT16
  - WNT5A
  - WNT5B
  - SLC6A4
  - hepatocellular carcinoma
  - breast cancer
  - 1-bladder cancer
  - bladder cancer
  - cancer
---
